• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

Recombinant Rat CD8A protein (rFc Tag)

Species

Rat

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg3839

Validation Data Gallery

  • Purity of Recombinant Rat CD8A was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

    Purity of Recombinant Rat CD8A was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

Product Information

Purity >90 %, SDS-PAGE
Endotoxin <0.1 EU/μg protein, LAL method
Activity 
Not tested
Expression HEK293-derived Rat CD8A protein Gln27-Tyr189 (Accession# P07725) with a rabbit IgG Fc tag at the C-terminus.
GeneID 24930
Accession P07725
PredictedSize 44.3 kDa
SDS-PAGE 48-55 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

CD8A, a member of the immunoglobulin superfamily, is primarily responsible for cell-mediated immune defense and T-cell development. CD8A, as an important member of the T-cytotoxicity pathway-associated genes, may be a useful biomarker of immunotherapeutic response and immune-cell infiltration, and has been widely reported to be a potential prognostic and diagnostic marker for a variety of disorders (e.g., inflammatory disorders and tumors). Studies have shown that CD8A expression is highly correlated with tumor mutational load, key immune checkpoint genes, and several types of tumor-infiltrating immune cells, predicting effective response to immunotherapy. Recent studies suggest that CD8A may be a potential prognostic marker for triple negative breast cancer (TNBC) and may also play a role in breast cancer (BC) metastasis.

References:

1. Zheng Z, et al. (2022) Cancers (Basel). 14(19):4866.                                                 
2. Chu J, et al.  (2024) Front Biosci (Landmark Ed). 29(2):73.                                           
3. Du Y, et al.  (2023) J Inflamm Res. 16:1653-1669.